These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20203496)

  • 1. Inflammation, peptides and biological therapy.
    Atreya R; Neurath MF
    Dig Dis; 2009; 27 Suppl 1():42-7. PubMed ID: 20203496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease.
    Atreya R; Atreya I; Neurath MF
    Ann N Y Acad Sci; 2006 Aug; 1072():98-113. PubMed ID: 17057193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
    Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
    Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 trans-signaling in inflammatory bowel disease.
    Mitsuyama K; Sata M; Rose-John S
    Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial NEMO links innate immunity to chronic intestinal inflammation.
    Nenci A; Becker C; Wullaert A; Gareus R; van Loo G; Danese S; Huth M; Nikolaev A; Neufert C; Madison B; Gumucio D; Neurath MF; Pasparakis M
    Nature; 2007 Mar; 446(7135):557-61. PubMed ID: 17361131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 and its activators in intestinal defense and mucosal homeostasis.
    Hruz P; Dann SM; Eckmann L
    Curr Opin Gastroenterol; 2010 Mar; 26(2):109-15. PubMed ID: 20040863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
    Gordon JN; Di Sabatino A; Macdonald TT
    Curr Opin Gastroenterol; 2005 Jul; 21(4):431-7. PubMed ID: 15930983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease.
    Uhlig HH; Powrie F
    Eur J Immunol; 2009 Aug; 39(8):2021-6. PubMed ID: 19672896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
    Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
    J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
    Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
    Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells.
    Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF
    Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
    Podolsky DK
    Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation.
    Shkoda A; Ruiz PA; Daniel H; Kim SC; Rogler G; Sartor RB; Haller D
    Gastroenterology; 2007 Jan; 132(1):190-207. PubMed ID: 17241871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic strategies for treatment of inflammatory bowel disease.
    Atreya R; Neurath MF
    Mucosal Immunol; 2008 May; 1(3):175-82. PubMed ID: 19079177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease: immunologic concepts.
    Schreiber S
    Hepatogastroenterology; 2000; 47(31):15-28. PubMed ID: 10690582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helminths and the modulation of mucosal inflammation.
    Elliott DE; Summers RW; Weinstock JV
    Curr Opin Gastroenterol; 2005 Jan; 21(1):51-8. PubMed ID: 15687885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?
    Reuter BK; Pizarro TT
    Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.